112 related articles for article (PubMed ID: 23523643)
1. Difficulty adhering to antidiabetic treatment: factors associated with persistence and compliance.
Guénette L; Moisan J; Breton MC; Sirois C; Grégoire JP
Diabetes Metab; 2013 May; 39(3):250-7. PubMed ID: 23523643
[TBL] [Abstract][Full Text] [Related]
2. Adherence to oral antidiabetic medications in the pediatric population with type 2 diabetes: a retrospective database analysis.
Adeyemi AO; Rascati KL; Lawson KA; Strassels SA
Clin Ther; 2012 Mar; 34(3):712-9. PubMed ID: 22381712
[TBL] [Abstract][Full Text] [Related]
3. A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid.
Oladapo AO; Barner JC; Rascati KL; Strassels SA
Clin Ther; 2012 Mar; 34(3):605-13. PubMed ID: 22386828
[TBL] [Abstract][Full Text] [Related]
4. Persistence and adherence to oral antidiabetics: a population-based cohort study.
Simard P; Presse N; Roy L; Dorais M; White-Guay B; Räkel A; Perreault S
Acta Diabetol; 2015 Jun; 52(3):547-56. PubMed ID: 25524433
[TBL] [Abstract][Full Text] [Related]
5. Important treatment gaps in vascular protection for the elderly after type 2 diabetes therapy initiation.
Guénette L; Breton MC; Hamdi H; Grégoire JP; Moisan J
Can J Cardiol; 2013 Dec; 29(12):1593-8. PubMed ID: 24183301
[TBL] [Abstract][Full Text] [Related]
6. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
7. Impact of cancer diagnosis on persistence of oral antidiabetic drugs.
Létinier L; Mansiaux Y; Pariente A; Fourrier-Réglat A
Diabetes Res Clin Pract; 2018 May; 139():323-330. PubMed ID: 29526679
[TBL] [Abstract][Full Text] [Related]
8. Persistence patterns with oral antidiabetes drug treatment in newly treated patients--a population-based study.
Grégoire JP; Sirois C; Blanc G; Poirier P; Moisan J
Value Health; 2010; 13(6):820-8. PubMed ID: 21054658
[TBL] [Abstract][Full Text] [Related]
9. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
Hertz RP; Unger AN; Lustik MB
Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
[TBL] [Abstract][Full Text] [Related]
10. Oral antidiabetic therapy in a large Italian sample: drug supply and compliance for different therapeutic regimens.
Vittorino Gaddi A; Benedetto D; Capello F; Di Pietro C; Cinconze E; Rossi E; De Sando V; Cevenini M; D'Alò G
Public Health; 2014 Jan; 128(1):70-6. PubMed ID: 23969148
[TBL] [Abstract][Full Text] [Related]
11. The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression.
Xing S; Calip GS; Leow AD; Kim S; Schumock GT; Touchette DR; Lee TA
J Diabetes Complications; 2018 May; 32(5):492-500. PubMed ID: 29544744
[TBL] [Abstract][Full Text] [Related]
12. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.
Cheong C; Barner JC; Lawson KA; Johnsrud MT
Clin Ther; 2008 Oct; 30(10):1893-907. PubMed ID: 19014846
[TBL] [Abstract][Full Text] [Related]
13. Underuse of cardioprotective treatment by the elderly with type 2 diabetes.
Sirois C; Moisan J; Poirier P; Grégoire JP
Diabetes Metab; 2008 Apr; 34(2):169-76. PubMed ID: 18396087
[TBL] [Abstract][Full Text] [Related]
14. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
Rashid N; McCombs JS; Schwartz E
Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
[TBL] [Abstract][Full Text] [Related]
15. Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus.
Mitchell BD; Eby EL; Lage MJ
Curr Med Res Opin; 2013 Dec; 29(12):1587-97. PubMed ID: 23886028
[TBL] [Abstract][Full Text] [Related]
16. Association Between Loyalty to Community Pharmacy and Medication Persistence and Compliance, and the Use of Guidelines-Recommended Drugs in Type 2 Diabetes: A Cohort Study.
Dossa AR; Grégoire JP; Lauzier S; Guénette L; Sirois C; Moisan J
Medicine (Baltimore); 2015 Jul; 94(27):e1082. PubMed ID: 26166087
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with antidiabetic medication non-adherence in patients with incident comorbid depression.
Lunghi C; Zongo A; Moisan J; Grégoire JP; Guénette L
J Diabetes Complications; 2017 Jul; 31(7):1200-1206. PubMed ID: 28325698
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemia-related emergency department visits and hypoglycemia-related hospitalizations among new users of antidiabetes treatments.
Moisan J; Breton MC; Villeneuve J; Grégoire JP
Can J Diabetes; 2013 Jun; 37(3):143-9. PubMed ID: 24070836
[TBL] [Abstract][Full Text] [Related]
19. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes.
Bebakar WM; Chow CC; Kadir KA; Suwanwalaikorn S; Vaz JA; Bech OM;
Diabetes Obes Metab; 2007 Sep; 9(5):724-32. PubMed ID: 17593237
[TBL] [Abstract][Full Text] [Related]
20. The Association between Depression and Medication Nonpersistence in New Users of Antidiabetic Drugs.
Lunghi C; Moisan J; Grégoire JP; Guénette L
Value Health; 2017 Jun; 20(6):728-735. PubMed ID: 28577689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
